CDC committee recommends opting for Pfizer or Moderna over J&J when there's a choice
ABC News
The rare blood clots are not a new safety concern, and the vaccine has already become far less common in the US.
The CDC's advisory committee recommended Thursday that people who have a choice should get an mRNA vaccine, either Pfizer or Moderna, over the single-shot Johnson & Johnson vaccine after a review of new CDC data on rare blood clots linked to J&J.
The rare blood clots are not a new safety concern, and the J&J vaccine has already become far less common in the U.S. after it was given an FDA warning label about the clotting condition. But more data that confirmed a slightly higher rate of clotting cases and deaths than was previously reported caused the CDC and FDA to take another look at the data this week.
The CDC has now confirmed a total of at least 54 cases and nine deaths from the severe clotting event, which is called thrombosis with thrombocytopenia or TSS, out of the 17 million people who have gotten the J&J vaccine in the US.
Though it's very rare, the data led CDC experts to favor mRNA vaccines by comparison, particularly because there are so many mRNA vaccines available in the US and people are less likely to be limited.
